Welcome to our dedicated page for Shattuck Labs SEC filings (Ticker: STTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission (SEC) filings for Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology company focused on autoimmune, inflammatory, and other immune-mediated diseases. Through these filings, investors can review how the company reports material events, financing transactions, and governance changes that affect holders of STTK common stock.
Shattuck’s Form 8-K current reports provide details on topics such as private placements of common stock and warrants, the terms of securities purchase agreements, and related registration rights agreements. These filings describe the structure of pre-funded warrants and common warrants, exercise price provisions, beneficial ownership limitations, and expected gross proceeds, as well as the company’s plans to register resales of the underlying shares.
Other 8-K filings furnish press releases announcing quarterly financial results, including research and development and general and administrative expenses, collaboration or license revenue, and net loss figures. While these press releases are often furnished rather than filed for Exchange Act purposes, they offer insight into Shattuck’s cash position and its expectations about how long existing capital and financing arrangements may support operations, subject to the risks noted in its periodic reports.
Filings also address governance matters, such as the resignation and appointment of directors, changes in board size, and committee assignments. For example, Shattuck has reported the addition of new directors associated with a significant private placement and described the rights of certain investors to designate board members under letter agreements.
By reviewing these SEC documents alongside AI-powered summaries, readers can quickly understand the key terms of Shattuck’s financings, the regulatory status of its securities, and the corporate actions that shape its capital structure and oversight. This filings archive complements Shattuck’s scientific and clinical disclosures by showing how those activities are reflected in its official regulatory reporting.
Amendment No. 3 to Schedule 13D filed by Redmile Group, LLC, Jeremy C. Green and Redmile Biopharma Investments II, L.P. discloses beneficial ownership and a private placement related to Shattuck Labs, Inc. (Common Stock, CUSIP 82024L103).
The Reporting Persons report beneficial ownership of 5,652,660 shares (11.8% of the class) based on 47,903,215 shares outstanding as of May 14, 2025. Holdings include 3,338,997 shares held by RBI II and specified holdings in multiple Redmile-managed funds. The filing states Redmile may be deemed to beneficially own 3,100,823 shares issuable upon exercise of Pre-Funded Warrants but those are entirely limited by a 9.99% Beneficial Ownership Blocker and thus excluded from the reported aggregate. The filing also notes 112,936 options exercisable within 60 days held by a Redmile managing director and assigned to Redmile.
On August 4, 2025 the Issuer entered a Purchase Agreement providing for a private placement of Pre-Funded Warrants and accompanying Common Warrants to purchase up to 4,097,730 shares (combined), at a combined price of $0.8676 per paired instrument; RBI II is to purchase 2,048,423 Pre-Funded Warrants and 2,048,423 Common Warrants. The closing is subject to satisfaction or waiver of several conditions including regulatory clearance of the Issuer's IND by the FDA. A side letter grants Redmile pro rata participation rights in future equity offerings and the right to designate a non-voting board observer, subject to maintaining certain ownership.